News & Events

Galway, Ireland — 12 January, 2016 — Neuravi, a company dedicated to improving clinical outcomes for stroke patients, was honored to meet with Ireland’s Prime Minister, Enda Kenny, last week at an event hosted by Enterprise Ireland in Amsterdam recognizing business agreements between Irish and Benelux companies.

Neuravi is building a strong market position in the Netherlands with notable deals and partnerships. In June 2015, Amsterdam-based healthcare investment firm Life Science Partners (LSP) led the €19M ($21M) Series B financing of Neuravi. In August 2015, Angiocare BV of Eemnes, the Netherlands, signed a distribution agreement with Neuravi to become the exclusive distributor of its EmboTrap® Revascularization Device in the Netherlands.

Paul Geudens, vice president of EMEA sales and marketing, represented Neuravi at the event. Joining him were Anne Portwich, partner at LSP and a Neuravi board member; Alexander de Vries, partner at Angiocare BV; and Professor Dr. Charles Majoie of the Academisch Medisch Centrum Amsterdam.

Professor Majoie was one of the lead investigators in the MR CLEAN trial, a study funded by the Dutch Heart Foundation and others, which produced the first definitive clinical evidence of the benefit of mechanical thrombectomy in treating large vessel acute ischemic stroke. Neuravi and Prof. Majoie’s team are collaborating on developing a better understanding of the clots that cause ischemic stroke.

“Ireland now has over 350 medtech firms employing 25,000 people with exports of around €8.5 billion a year. Neuravi has emerged as a leader in this sector and its commercial progress in Europe has been impressive. I am delighted to introduce Neuravi and its partners to the Taoiseach (Prime Minister) to recognise these important contributions to business and healthcare in the Benelux region. These collaborations reflect Neuravi’s depth of commitment in addressing the needs of stroke-affected patients,” stated Julie Sinnamon, CEO, Enterprise Ireland.

Paul Geudens commented, “Neuravi recognizes the value in partnering with outstanding organizations in order to build a strong presence in the Netherlands. We are proud to team with Dutch leaders like LSP and Angiocare. We also look forward to our collaborative work with Prof. Majoie on better understanding the characteristics of clot that cause stroke and the implications for treatment.”

“While the field of stroke therapy has advanced tremendously over this past year, significant opportunity remains to further improve patient outcomes,” noted Professor Majoie. “Studying the culprit clot is one of the areas likely to impact treatment strategies, and so our work with Neuravi will be valuable in this endeavor.”

Enterprise Ireland is the government organization responsible for the development and growth of Irish enterprises in world markets. It works in partnership with Irish enterprises to help them start, grow, innovate and win export sales in global markets.

About Neuravi
Based in Galway, Ireland, Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s initial stroke therapy platform, the EmboTrap Revascularization Device, is CE marked, and commercially available in Europe. Neuravi’s ARISE II clinical trial has started enrolling patients at select centers in the United States and Europe. The trial will gather data to support the use of the EmboTrap and to seek FDA approval. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke. Neuravi is led by a team experienced in endovascular device development and global commercialization. More information can be found at www.neuravi.com.

About Neuravi

Led by a team experienced in endovascular device development and global commercialization, the company’s initial technology platform addresses acute ischemic stroke. In collaboration with international researchers and clinicians, the company seeks to develop new understanding that will drive innovative solutions to treat this challenging and devastating disease. In April 2017, Codman Neuro announced the acquisition of Neuravi, leading to the formation of Cerenovus, part of the Johnson and Johnson family of medical device companies.

Team

Contact Us

The EmboTrap® device and EmboTrap®II device are CE-Marked. Caution — Investigational Device. Limited by Federal Law to Investigational Use.

Seán Mac Réamoinn

CFO

Seán is a finance and business leader who has led multiple corporate transactions including mergers, acquisitions, funding rounds and IPOs. Having worked with a range of businesses across the manufacturing, financial and technology sectors, Seán was Head of Finance in the e-business solutions division of Horizon Technology Group plc at a time of rapid growth and during their IPO. He was also a co-founder of mobile technology provider zamano and led it from foundation and ultimately through to a successful listing on the London Stock Exchange.

Justin Lynch

Director

Justin Lynch is a Partner in Fountain Healthcare Partners and also serves as the CFO of the firm. He joined the team in early 2007 prior to the launch of Fund I in 2008. Justin has a BA in Accounting & Finance from Dublin City University, an MBA from Trinity College Dublin and is a member of the Chartered Institute of Management Accountants. He has over 25 years experience in capital markets, corporate finance, entrepreneurial and venture investing across multiple sectors, the latter half in life science. Justin has a particular interest in the medical device sector and leads the firms investments in Neuravi and Vivasure Medical where he also serves as a board member.

Joey Mason

Director

Dr Joey Mason joined Delta Partners in 2003, specialising in Life Science investments. His current focus is on medical technologies and Health IT. He serves on the boards of Genable Ltd, Glysure Ltd, Miracor Medical Systems GmbH, SpineGuard SA, Accunostics Ltd and Neuravi Ltd. He acts as an observer on the board of QStream, Inc. and previously served on the board of Heartscape Technologies, Inc., prior to its sale.

Joey serves on the board of EVCA (the European Private Equity and Venture Capital Association) and on its constituent Venture Capital platform.

Having trained as a doctor at Trinity College, Dublin, Joey spent five years as an investment banker in the Health Care sector with Morgan Stanley International and Technomark in London. From 1995 until 1999 he was Director of Corporate Development at Biotrin Holdings plc, an Irish immuno-diagnostics company specialising in infectious diseases and organ damage and backed by Delta Partners and other leading international VCs.

In 2000 he co-founded and managed Eumom Ltd, a marketing services business operating websites for pregnant women in Germany, Ireland, Switzerland and the UK.

Chloe Brown

Director Market Development

Chloe has 10 years experience in interventional neurovascular sales and marketing, launching several game-changing technologies including Onyx, Pipeline and Solitaire FR. Most recently, Chloe led the European Marketing and Market Development Activities in Acute Ischemic Stroke for Covidien. Chloe developed the Stroke Centre of Excellence Programs with 5 key Stroke Institutions across Europe which trained over 400 physicians. Chloe was instrumental in developing partnerships between Covidien and both the European and World Stroke Organisations.

Jill Amstutz

VP Global Marketing

With over 20 years of experience in the medical device industry, Jill leverages strategic marketing skills as a collaborative project leader for early stage medical device companies. She guided market-focused product development of neurointerventional stroke therapies at Micrus Endovascular and Guidant Compass. Part of the early team at Sadra Medical, which was acquired by Boston Scientific, she played a leadership role in developing Lotus University. Jill has an MBA from the Stanford GSB and a BA from Princeton University.

Paul Geudens

VP EMEA Sales and Marketing

Paul is a successful leader within the medical device industry having run sales and marketing organizations in both startup and Fortune 100 companies. Most recently, Paul led the market entry efforts for Surpass Medical, which was later acquired by Stryker for $135M in 2012, served as VP of Sales and Marketing for Stentys, and acted as Executive VP of Operations at Caliber Therapeutics. Prior to his startup endeavors, Paul spent 12 years with Johnson & Johnson in senior leadership positions across the company’s cardiovascular franchise.

Michael Gilvarry

VP of R&D and Technical Operations

An experienced R&D leader, Michael has worked in the medical device industry for over 15 years. Prior to joining the Neuravi team, he was an R&D Manager at Abbott Vascular where he successfully led the development of the EmboShield NAV6 Embolic Protection System and played a key role in the US launch of the Xact Carotid Stent. He is a named inventor on over 40 US patents, granted or pending.